Oryzon Genomics SA Email Format
Biotechnology ResearchCatalonia, Spain51-200 Employees
Oryzon Genomics SA is a clinical‑stage biopharmaceutical company based in Barcelona, Catalonia, with operations spanning Barcelona, Boston, and New Jersey. It operates in the biotechnology research sector and centers its work on epigenetics, aiming to advance personalized medicine for central nervous system disorders and oncology/heamatology. The company is building a portfolio around two differentiated LSD1 inhibitors, with iadademstat pursuing oncology/hematology applications in multiple Phase I and II trials and reporting strong signals in acute myeloid leukemia, while vafidemstat targets neuropsychiatric conditions and is advancing through Phase IIb and Phase III preparations for specific indications. Oryzon is also exploring additional targets, such as HDAC6, and maintains a biomarker platform to support precision medicine approaches. A notable recent development is the company’s planned presentations at the European Hematology Association Annual Congress, reflecting ongoing clinical progress and data updates.